Insulin-Sensitizing Effects of Omega-3 Fatty Acids: Lost in Translation?
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing preclinical mechanisms and human studies without systematic review methodology.
PubMed 27258299 · doi:10.3390/nu8060329
What was done
The authors reviewed preclinical and clinical literature (focusing on studies published within the two years prior along with representative earlier works) to evaluate the therapeutic potential and mechanisms of marine omega-3 polyunsaturated fatty acids (EPA and DHA) on insulin sensitivity in skeletal muscle, liver, and adipose tissue.
What was found
The abstract reports no numerical data. It notes a major translational discrepancy: rodent studies consistently demonstrate insulin-sensitizing benefits from n-3 PUFA supplementation, and human observational studies show positive associations, but the vast majority of randomized human intervention trials fail to show improvements in insulin sensitivity in individuals with type 2 diabetes or non-diabetic insulin resistance.
Why it matters
This review highlights a significant translational failure between rodent models and human trials, cautioning against assuming marine omega-3 supplements improve insulin resistance in clinical practice.
Limits
The paper is a narrative commentary without formal systematic review methodology, quantitative meta-analysis, or risk-of-bias grading. The abstract provides no exact study counts, sample sizes, doses, or treatment durations.
Cited by
- supports In rodent studies, omega-3 supplementation has positive effects on insulin sensitivity and glucose regulation, but evidence in humans is mixed and less convincing.